Regenxbio (RGNX) Tops Q4 EPS by 14c

Regenxbio (NASDAQ: RGNX) reported Q4 EPS of ($0.20), $0.14 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $4.4 million versus the consensus estimate of $1.23 million.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Element Solutions (ESI) PT Lowered to $47 at UBS, Buy Rating Maintained
• UBS Reiterates Neutral Rating on Intuit (INTU), Says Investor Day Not 'Sentiment-Changing'